Meeting
2023 ASCO Annual Meeting
Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival.
Authors
Lakshmi Bhavani Potluri
Wayne State Univ/DMC Sinai Grace Hospital, Detroit, MI 48235, Detroit, MI
Lakshmi Bhavani Potluri , Hannah Seah , Vaishnavi Reddy Bade , Arthur Krogman , Shree Acharya , Andreea Mihaela Negroiu , Srikanth Talluri , Lakshmi Manasa Vempati , Pradyumna Iragavarapu , Saem Lee , Mariateresa Fulciniti , Mehmet Kemal Samur , Paul G. Richardson , Philippe Moreau , Herve Avet-Loiseau , Kenneth Carl Anderson , Rao H. Prabhala , Nikhil C. Munshi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8016)
DOI
10.1200/JCO.2023.41.16_suppl.8016
Abstract #
8016
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Prevalence of ocular comorbidities in patients with multiple myeloma: An analysis of U.S. claims data.
First Author: Sikander Ailawadhi
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1.
First Author: Sébastien Wieckowski
Poster
2024 ASCO Genitourinary Cancers Symposium
Atezolizumab plus personalized neoantigen vaccination (PGV001) in patients with urothelial cancer.
First Author: Jonathan Forrest Anker
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
First Author: Michael Bitzer